

26. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

27. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.


28. The composition of Claim 10, wherein the prevention and/or treatment of Parkinson's disease involves at least one other therapeutic agent comprising levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

29. The use of Claim 11, wherein the medicament comprises at least one other therapeutic agent selected from levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

30. A kit comprising:

- a container having an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof; and
- instructions for using the same to prevent and/or treat Parkinson's disease.


26. The compound of Claim 16, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

27. The use of Claim 17, wherein the compound is:



,

or a pharmaceutically acceptable salt, or solvate thereof.

28. The composition of Claim 10, including at least one other therapeutic agent comprising levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

29. The use of Claim 11, wherein the medicament comprises at least one other therapeutic agent selected from levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.

30. A kit comprising:

- a container having an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof for use in the prevention or treatment of Parkinson's disease; and
- instructions for using the same.